Overview MDL MFCD29472270 Molecular Weight 398.85 Molecular Formula C19H19ClN6O2 SMILES C([C@@H](NC(=O)C=1C=C(C(C)O)NN1)C)N2N=C(C=C2)C3=CC(Cl)=C(C#N)C=C3
For research use only.
Storage 3 years,-20°C,powder 1 years,-80°C,in solvent
Shipping Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions Concentration Volume Mass 1 mg 5 mg 10 mg 1 mM 2.5072 mL 12.5360 mL 25.0721 mL 5 mM 0.5014 mL 2.5072 mL 5.0144 mL 10 mM 0.2507 mL 1.2536 mL 2.5072 mL 50 mM 0.0501 mL 0.2507 mL 0.5014 mL
Description Darolutamide (ODM-201, BAY-1841788) is a novel (AR) antagonist that blocks AR nuclear translocation with of 11 nM. Phase 3.
Targets Androgen receptor [1] 11 nM(Ki)
In vitro In AR-HEK293 cells stably expressing full-length hAR, ODM-201 inhibits human AR (hAR) with IC50 of 26 nM. ODM-201 inhibits VCaP cell proliferation with IC50 of 230 nM, while has no effect on the viability of AR-negative cell lines tested, DU-145 prostate cancer cells and H1581 lung cancer cells.
In vivo In mice bearing VCaP xenografts, ODM-201 (50 mg/kg, p.o.) significantly inhibits castration-resistant prostate tumor growth.
Synonyms 1H -Pyrazole-3-carboxamide, N -[(1S )-2-[3-(3-chloro-4-cyanophenyl)-1H -pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-
N -[(1S )-2-[3-(3-Chloro-4-cyanophenyl)-1H -pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H -pyrazole-3-carboxamide
Darolutamide
ODM 201
BAY 1841788
Nubeqa